Skip to main content

Eradigm's latest thinking from the cutting edge of Pharma

Filter

Preparing Healthcare Systems for Broader CGT Access: What Needs to Change for Pharma, Healthcare Systems, and Patients so All Benefit from Cell & Gene Therapies?
Preparing Healthcare Systems for Broader CGT Access: What Needs to Change for Pharma, Healthcare Systems, and Patients so All Benefit from Cell & Gene Therapies?

Preparing Healthcare Systems for Broader CGT Access: What Needs to Change for Pharma, Healthcare Systems, and Patients so All Benefit from Cell & Gene Therapies?

17 min
Collaborating for better outcomes: How can value-based partnerships unlock value across stakeholder groups and elevate pharma’s role within healthcare ecosystems?
Collaborating for better outcomes: How can value-based partnerships unlock value across stakeholder groups and elevate pharma’s role within healthcare ecosystems?

Collaborating for better outcomes: How can value-based partnerships unlock value across stakeholder groups and elevate pharma’s role within healthcare ecosystems?

15 min
The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period
The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

10 min
The evolving role of provider, payer, and patients in biosimilar adoption - how does this affect successful commercialization of biosimilars in EU4+UK?
Access for all
The evolving role of provider, payer, and patients in biosimilar adoption - how does this affect successful commercialization of biosimilars in EU4+UK?

The evolving role of provider, payer, and patients in biosimilar adoption - how does this affect successful commercialization of biosimilars in EU4+UK?

22 min
How Should Pharmaceutical Companies Plan Launch Strategies in Europe’s Cost-Saving Environment?
How Should Pharmaceutical Companies Plan Launch Strategies in Europe’s Cost-Saving Environment?

How Should Pharmaceutical Companies Plan Launch Strategies in Europe’s Cost-Saving Environment?

20 min
What are the pricing and repricing mechanisms in Japan’s P&R system that pharma must understand when considering a launch in Japan?
What are the pricing and repricing mechanisms in Japan’s P&R system that pharma must understand when considering a launch in Japan?

What are the pricing and repricing mechanisms in Japan’s P&R system that pharma must understand when considering a launch in Japan?

15 min
Preparing for successful market access and HTA assessments in Europe
Preparing for successful market access and HTA assessments in Europe

Preparing for successful market access and HTA assessments in Europe

13 min
The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period
The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

10 min
Hail the Slow Burner – now’s the time to fire up your Cross-Portfolio Competitive Intelligence Function
Hail the Slow Burner – now’s the time to fire up your Cross-Portfolio Competitive Intelligence Function

Hail the Slow Burner – now’s the time to fire up your Cross-Portfolio Competitive Intelligence Function

14 min

Our Mission     Our Services     Our Team     Insights     Careers     Contact Us

Our Mission     Our Services     Our Team     Insights     Careers     Contact Us